Earnings results for Cassava Sciences (NASDAQ:SAVA)
Cassava Sciences, Inc. is estimated to report earnings on 11/10/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.07. The reported EPS for the same quarter last year was $-0.04.
Cassava Sciences last posted its quarterly earnings results on August 12th, 2020. The reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. Cassava Sciences has generated ($0.27) earnings per share over the last year. Cassava Sciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 10th, 2020 based off prior year’s report dates.
Analyst Opinion on Cassava Sciences (NASDAQ:SAVA)
3 Wall Street analysts have issued ratings and price targets for Cassava Sciences in the last 12 months. Their average twelve-month price target is $19.33, predicting that the stock has a possible upside of 90.29%. The high price target for SAVA is $24.00 and the low price target for SAVA is $14.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Cassava Sciences has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $19.33, Cassava Sciences has a forecasted upside of 90.3% from its current price of $10.16. Cassava Sciences has only been the subject of 3 research reports in the past 90 days.
Dividend Strength: Cassava Sciences (NASDAQ:SAVA)
Cassava Sciences does not currently pay a dividend. Cassava Sciences does not have a long track record of dividend growth.
Insiders buying/selling: Cassava Sciences (NASDAQ:SAVA)
In the past three months, Cassava Sciences insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $1,657,959.00 in company stock and sold $0.00 in company stock. Only 13.70% of the stock of Cassava Sciences is held by insiders. Only 24.07% of the stock of Cassava Sciences is held by institutions.
Earnings and Valuation of Cassava Sciences (NASDAQ:SAVA
Earnings for Cassava Sciences are expected to grow in the coming year, from ($0.25) to $0.86 per share. The P/E ratio of Cassava Sciences is -46.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Cassava Sciences is -46.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Cassava Sciences has a P/B Ratio of 10.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here